SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

New 24-month HOPE-3 extension data presented at the World Muscle Society, showing slower upper-limb decline after patients switched to deramiocel, has fueled renewed attention to Capricors Duchenne muscular dystrophy therapy. Traders are encouraged by the results but debate whether they will overcome the FDAs prior efficacy and statistical-analysis concerns ahead of its review decision.

Goodyear Tire & Rubber Co. engages in the development, manufacture, distribution, and sale of tires. It operates through the following geographical segments: Americas, Europe, Middle East, and Africa, and Asia Pacific. The Americas segment is involved in the development, manufacture, distribution, and sale of tires and related products and services in North, Central, and South America. The Europe, Middle East, and Africa segment focuses on the development, manufacture, distribution, and sale of tires for automobiles, trucks, buses, aircraft, motorcycles, earthmoving, mining, and industrial equipment throughout Europe, the Middle East, and Africa. The Asia Pacific segment refers to the development, manufacture, distribution, and sales of tires for automobiles, trucks, buses, aircraft, farm, earthmoving, mining, and industrial equipment throughout the Asia Pacific region. The company was founded by Frank A. Seiberling on August 29, 1898 and is headquartered in Akron, OH.

Goodyear Tire & Rubber Co.

Goodyears prolonged slide toward multi-year lows and intermittent sharp moves have fueled debate over its heavy debt and bankruptcy risk versus its low valuation and short-interest-driven rebound potential. Traders speculate about a buyout or short squeeze, but no specific deal or other confirmed catalyst is established in the discussion.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

ZBCNs sharp rally has traders watching for a technical breakout and linking the move to broader altcoin momentum. Optimism about further gains is tempered by concerns that the rally could fade; Robinhood and BlackRock-related explanations remain speculation, not confirmed catalysts.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Deutsche Banks upgrade of Netflix to Buy after its steep selloff is drawing attention, with the bullish case emphasizing international engagement and valuation despite concerns about weaker U.S. viewing and competition from YouTube. Traders remain divided: some see the upgrade as support for a rebound, while others argue it does not resolve worries about engagement, content, and persistent selling pressure.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is drawing attention for a reported breakout toward fresh highs as traders see the Magnificent Seven regaining market leadership and supporting the broader indexes. The reaction is mostly bullish, though some caution that gains are concentrated in mega-cap tech and debate whether the strength can broaden beyond the group.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

AbCellera is drawing attention after JPMorgan initiated coverage with an Overweight rating, citing promising ABCL635 results, while traders focus on the drugs Phase 2 data and a planned detailed presentation. The community is broadly bullish on the menopause-treatment candidate and the companys pipeline, though some caution that efficacy and safety still need validation in larger trials and debate whether the stocks sharp run-up may pull back.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances higher full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, drove the sharp rally and renewed analyst attention. Traders are broadly bullish and discussing a possible short squeeze, while some caution that the move may be overextended and debate dilution risk ahead of lung-cancer data.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns fiscal Q4 earnings and guidance are the dominant focus, with traders watching for signs that AI-driven HBM demand and tight DRAM/NAND supply can sustain strong growth. Many expect a strong report, while others warn that high expectations and uncertainty over how long the memory upcycle will last could prompt a sell-the-news reaction.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings sharp selloff is being linked to competition from Kalshi and Polymarket in sports prediction markets, regulatory uncertainty, and concern that added DKeX investment could pressure profits. Traders are divided: bears see rivals taking share, while bulls point to DKeXs rising volume and sportsbook growth as signs DraftKings can compete.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 
